

Supplementary Table 1. Study flow chart

Data points	Baseline	Follow-up 1	Follow-up 2
Visit number	1	2	3
Week(s)	0	12	24
Informed consent	X		
Diagnosis	X		
Inclusion/exclusion criteria	X		
Demographics	X		
Family history of T2DM	X		
Diabetic complications	X		
Medical history	X		
Physical examination	X	X	X
Anti-hyperglycemic agents	X	X	X
Concomitant medications	X	X	X
Empagliflozin administration status	X	X	X
Renal function	X ^a	X ^a	X ^a
Effective endpoints	X	X	X
The final efficacy evaluation			X
Change in lab tests		X ^a	X ^a
Adverse events		X	X
Study completion		X	X

T2DM, type 2 diabetes mellitus.

^aIf available.